gp140-anti-CD40 antibody fusion protein vaccine (Baylor Scott & White Research Institute/ANRS)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namegp140-anti-CD40 antibody fusion protein vaccine (Baylor Scott & White Research Institute/ANRS)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedVaccines > Application > Prophylactic vaccineBiologics > Protein drugs > Recombinant protein > Fusion protein +[4]

Mechanisms of ActionEnvelope glycoprotein gp160 modulatorsTumor necrosis factor receptor superfamily member 5 modulators

TargetsTumor necrosis factor receptor superfamily member 5Envelope glycoprotein gp160

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesFrance

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBaylor Scott & White Research Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAgence Nationale de Recherches sur le Sida et les hepatites virales (ANRS)Baylor Scott & White Research Institute

Active IndicationsN/A

Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A